SCHEMBL9963241

SCHEMBL9963241

COc1ccc(C2(CNC(=O)C(C)(C)C)CCN(C(C)C)CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 3/20 0.47
CHRM1 P11229 3/20 0.47
CHRM3 P20309 3/20 0.47
POLB P06746 2/20 0.47
HTT P42858 1/20 0.47
P2RX7 Q99572 4/20 0.47
ALDH1A1 P00352 2/20 0.47
SOAT1 P35610 2/20 0.45
MMP1 P03956 1/20 0.45
MMP9 P14780 1/20 0.45
MMP13 P45452 1/20 0.45
KMT2A Q03164 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KCNA3 P22001 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
DRD4 P21917 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9965988 0.88 CHRM5 (0.60) CHRM5CHRM1CHRM3POLBP2RX7
SCHEMBL18159189 0.74 POLB (0.61) POLBP2RX7ALDH1A1KMT2AL3MBTL1
SCHEMBL21214320 0.73 DRD3 (0.54) P2RX7SMN1; SMN2DRD4
SCHEMBL18159191 0.73 POLB (0.60) POLBP2RX7ALDH1A1KMT2AL3MBTL1
SCHEMBL19652200 0.73 SIGMAR1 (0.34) MMP1MMP9MMP13
SCHEMBL23384021 0.70 OPRM1 (0.67) POLBHTTALDH1A1MMP1MMP9
SCHEMBL20315428 0.68 CYP3A4 (0.61) ALDH1A1MMP1MMP9MMP13KMT2A
SCHEMBL9428083 0.68 P2RX7 (0.61) CHRM5CHRM1CHRM3POLBP2RX7
SCHEMBL29071771 0.67 NPSR1 (0.49) POLBHTTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL3277267 0.67 HRH3 (0.64) POLBHTTALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 CHRM5 156/4885CHRM1 77/4885CHRM3 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.